Ascentage Pharma to Attend 3 Investor Conferences in September
Ticker: AAPG · Form: 6-K · Filed: Aug 28, 2025 · CIK: 2023311
Sentiment: neutral
Topics: investor-relations, conference-participation
TL;DR
Ascentage Pharma is hitting up 3 investor conferences in Sept - good sign for engagement.
AI Summary
Ascentage Pharma Group International announced on August 25, 2025, that it will participate in three investor conferences in September 2025. The company, located at 68 Xinqing Road, Suzhou Industrial Park, China, is a pharmaceutical preparations company.
Why It Matters
This indicates the company is actively engaging with investors, which can be a positive sign for future funding and market perception.
Risk Assessment
Risk Level: low — The filing is a routine announcement of conference participation, not indicating any significant financial or operational changes.
Key Players & Entities
- Ascentage Pharma Group International (company) — Registrant
- August 25, 2025 (date) — Press release date
- September 2025 (date) — Conference participation period
- 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (location) — Company address
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is to furnish a press release dated August 25, 2025, announcing Ascentage Pharma's participation in three upcoming investor conferences in September 2025.
When was the press release issued?
The press release was issued on August 25, 2025.
What is the main topic of the press release?
The press release announces that Ascentage Pharma will participate in three upcoming investor conferences in September 2025.
Where is Ascentage Pharma Group International located?
Ascentage Pharma Group International's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Does Ascentage Pharma file annual reports under Form 20-F or 40-F?
Ascentage Pharma indicates it files annual reports under cover of Form 20-F.
Filing Stats: 195 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2025-08-28 16:15:26
Filing Documents
- ea0254405-6k_ascentage.htm (6-K) — 11KB
- ea025440501ex99-1_ascentage.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001213900-25-081751.txt ( ) — 51KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On August 25, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated August 25, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: August 28, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3